ArticleGeroScience2026
Peucedanum japonicum Thunb. ameliorates age-related muscle loss by improving mitochondrial function in aged mice.
Article in GeroScience, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
Abstract
Peucedanum japonicum Thunb. (PJ), also known as costal hog fennel, is an edible medicinal plant recognized for its potential health benefits. We previously demonstrated the protective effects of PJ against muscle atrophy in young mice. In the present study, we investigated whether PJ also inhibits age-related muscle loss in aged mice. PJ treatment of primary myoblasts derived from aged mice attenuated myotube diameter reduction, suppressed the expression of atrogenes, and prevented the fast-to-slow myosin heavy chain (MHC) fiber type transition. Additionally, PJ improved mitochondrial respiratory capacity, accompanied by increased PGC1α expression and phosphorylation. Aged mice (20 months old) were fed diets supplemented with 0.1% or 0.2% PJ for eight weeks. PJ supplementation enhanced muscle strength and physicalrformance parameters, including treadmill endurance and stride length. Increases in lean body mass, muscle weight, cross-sectional area (CSA), and the ratio of MHCII to MHCI fibers were observed. These improvements were associated with reduced ubiquitin-dependent protein degradation and the downregulation of atrogenes. Furthermore, PJ supplementation promoted mitochondrial activity via PGC1α and stimulated mitochondrial biogenesis through the Nrf1-Tfam pathway. 4-Caffeoylquinic acid (4-CQA), a major bioactive compound in PJ, attenuated myotube atrophy and enhanced mitochondrial respiration in aged myoblasts. These findings suggested that PJ, along with its active compound 4-CQA, has therapeutic potential for combating age-related muscle loss.
Indexed as
Identifiers
41701439What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.